Popular Articles

Blogs Comment On Women's Health Disparities, Sotomayor Nomination, Other Topics
The following summarizes selected women"s health-related blog entries. ~ "Report: Higher Rates of Unintended Pregnancy, Abortion Among Women of Color," Sharon Camp, RH Reality Check: A new report from the Kaiser Family Foundation on health disparities between white women and women of color "provides further stronger evidence debunking claims" from antiabortion-rights advocates who "have long argued that high abortion rates among minorities are the result of supposed aggressive marketing by abortion providers to minority communities," Camp, president and CEO of the Guttmacher Institute, writes. In addition to identifying disparities in conditions like heart disease and cancer, the report documents "widespread disparities in access to health insurance and health screenings" and explores growing evidence of the association between social factors and health behaviors, access and outcomes, according to Camp. She continues that research from Guttmacher has consistently demonstrated that "rates among racial and ethnic minorities -- especially blacks and Hispanics -- are directly linked to their higher rates of unintended pregnancy, which in turn reflect pervasive health disparities more generally." Camp writes that the "fundamental question policymakers should be asking is not why women of color have high abortion rates, but rather what can be done to help them have fewer unintended pregnancies and achieve better health outcomes more generally," such as improved access to affordable contraception. Women"s dissatisfaction with health care providers, quality of service and the contraceptive methods themselves also are factors in contraceptive use, as are "[u]nstable life situations," which can make consistent use a low priority for some women, according to Camp. She writes, "By continuing to label abortion providers as "racists" and refusing to support expanded access to contraceptive services, antiabortion-rights activists are by no means part of the solution -- to high rates of unintended pregnancy and abortion among racial and ethnic minorities or to persistent and tragic disparities in health care generally" (Camp, RH Reality Check, 6/15).~ "What"s Next for Women"s Legal Rights in the Supreme Court?" Amy Matsui, Womenstake: Matsui, senior counsel for the National Women"s Law Center, examines several women"s rights issues "that we see peeking around the corner" of the next Supreme Court session. Matsui writes that "increasingly draconian abortion restrictions have begun to work their way through state legislatures." These restrictions include giving personhood rights to fetuses, mandates on the information women are given prior to abortion procedures and "outright abortion bans," she writes. Challenges to laws that expand protections for providers who deny health care services also "are likely to come before the courts," Matsui writes. Challenges to health care reform proposals also are likely, "specifically, the interaction of the federal statute that governs employee health care and pension plans ... and any new requirements for employers to provide health care coverage," according to Matsui. The Supreme Court has "obviously considered the underlying legal doctrines in these cases (the constitutional right to privacy, federal anti-discrimination statutes, Equal Protection guarantees and federal benefits statutes) in the past; some might say that there is a clear roadmap of where the Court should go in some of these cases," Matsui writes, concluding, "But when every vote counts on the Supreme Court, women should be watching what cases come next" (Matsui, Womenstake, 6/12).~ "Antiabortion Groups" Case Against Sotomayor," Dan Gilgoff, U.S. News & World Report"s "God and Country": "With no clear evidence for a pro-abortion-rights position in her judicial decisions, antiabortion groups" case against Supreme Court nominee Sonia Sotomayor can be summed up in eight words: the Puerto Rican Legal Defense and Education Fund," Gilgoff writes. From 1980 to 1992, Sotomayor sat on the l
diet pills
Pitt's Dr. Lewis Kuller Named 2009 Distinguished Scientist By American Heart Association
Lewis Kuller, M.D., Dr.P.H., distinguished professor of public health and professor of epidemiology at the University of Pittsburgh Graduate School of Public Health, has been designated a 2009 American Heart Association Distinguished Scientist for major contributions to cardiovascular disease and stroke research.
News of the day
Interim Study Results Presented At ADA 2009: Exenatide Not Associated With Increased Rate Of Acute Pancreatitis Compared To Other Antidiabetic Drugs
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced interim results from a retrospective study including nearly 260,000 patients that showed the risk of acute pancreatitis among patients initiating therapy with BYETTA(R) (exenatide) injection was not increased compared to patients initiating other antidiabetic therapies. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans.
Medical Devices

Teva And Antares Announce FDA Approval Of Needle-Free Injector Product For Administration Of Tev-Tropin(R) (Human Growth Hormone)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and its partner, Antares Pharma, Inc. (NYSE Amex: AIS) announced the approval of a Supplemental New Drug Application (sNDA), which added "needle-free injection" to its Tev-Tropin® [somatropin (rDNA) for injection] brand human growth hormone (hGH) drug label. Teva will market the Antares needle-free device as the Tev-Tropin Tjet Injector system. "We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares, and to offer patients a less invasive delivery system," stated Larry Downey, head of Teva"s North America Brand Pharmaceuticals division. "This significant achievement demonstrates our ability to leverage our leadership in the pharmaceutical industry, and our ongoing commitment to utilize our global strengths in innovative activities." "This is the first product approval stemming from our portfolio of product collaborations with Teva and is a very exciting milestone for the Company" said Paul K. Wotton, President and Chief Executive Officer of Antares Pharma. "Importantly it is another example of delivering on our strong focus and commitment to patients, together with our partners, to provide new ways to administer drugs. We look forward to the launch of this product by Teva." Human growth hormone is a protein given by injection that is commonly used to treat children with growth hormone deficiency. Pediatric patients benefit both from the avoidance of using needles as well as the rapid injection speed associated with giving needle-free injections. According to industry estimates, the market for human growth hormone in the United States is approximately $1 billion which is the largest market segment globally. Antares currently markets its needle-free injection system for use in the treatment of growth hormone deficient children through its partners in Europe, Japan and Asia. Tev-Tropin®


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):